ATENOLOL

 

StockNo	Product description
EB0280-424-03	ATENOLOL 50 MG X 30 FILMTABL
EB0280-424-29	ATENOLOL 100 MG X 30 FILMTABL

 

COMPOSITION:
Atenolol 50 mg; 100 mg in one filmtablet

ACTION:
Atenolol is a cardioselective B1-adrenoblocker without internal sympathomimetic activity and membrane-stabilizing action. It reduces the arterial pressure associated with the reduction of cardiac minute volume, without essentially changing the peripheral vascular resistance. Renin secretion is inhibited. Its antianginal action is associated with the reduced oxygen needs of the myocardium resulting from the negative bathmotopic, chronotropic and inotropic effect on the myocardium. Its action on the cardiac rhythm conductivity determines its antiarhythmic action.

PHARMACOKINETICS:
Atenolol is water-soluble and readily absorbed in the gastrointestinal tract, it is excreted unchanged with the urine, being slightly metabolized in the liver. Maximum plasma concentrations are attained after 2-4 h. its half-elimination time is about 6 h if the renal function is undamaged.

INDICATIONS:
Ischemic heart disease. All forms of angina pectoris, with the exception of Prinzmetal's angina, are susceptible to atenolol treatment. It is administered in arterial hypertension of various origin, including renal. Disorders of cardiac rhythm: sinus tachycardia, paroxysmal supraventicular tachycardia, non-paroxysmal superventicular arrhythmia, including WPW syndrome. Atenolol is an agent of choice in the treatment of arrhythmias in thyrotoxicosis, tachyarrhythmia induced by digitalis intoxication. It is administered in functional cardiovascular disorders, added to the combined therapy of cardiomyopathies and tetralogy of Fallot.

CONTRAINDICATIONS:
Manifest cardiac insufficiency, cardiogenic shock, heart block, AV-block of II and II degree are absolute contraindications, as well as sinus bradycardia (under 45 beats), hypotension in myocardial infarction (systolic pressure below 100 mg Hg).
Relataive contraindications: bronchial asthma and severe spastic bronchitis, emphysema, allergy to other pharmaceuticals, congestive cardiac insufficiency, diabetes mellitus, deteriorated renal function, psoriasis, etc.

DRUG INTERACTIONS:
The cardiodepressive action of atenolol is enhanced by simultaneous intake of antiarrhythmic agents, another beta-receptor blocker, anesthetics, calcium antagonists, narcotics, neuroleptics, tricyclic antidepressants. Parallel administration with insulin or sulfanylurea drugs can impede the control of their hypoglycemic action. A very sharp and strong reduction of blood pressure can be induced by parallel administration with some other antihypertensive agents. Its effect is reduced by calcium antagonists.

PRECAUTIONS:
Atenolol treatment should not abruptly be discontinued, but with a gradual reduction of the dose.

DOSAGE AND ADMINISTRATION:
Arterial hypertension - the treatment starts with 50-100 mg daily, the dose being increased by 100 mg within 1-3 weeks until the optimum hypotensive effect is attained. Maximum dose - 300 mg in a single intake or divided into 2-3 intakes. In stable angina pectoris the treatment starts with 50 mg, 2 times daily and in the absence of effect the daily dose is increased by 50 mg every 1-2 weeks till the optimum anti-anginal effect is attained, hemodynamic beta-adrenergic blockade, occurrence of adverse effects, or to a maximum dose of 300 mg (100 mg 3 times). The mean effective dose is 100 mg, in a single intake or in two intakes daily.
In renal insufficiency with creatinine clearance of 15-30 ml/min, the dose is 50 mg daily or 100 mg every second day; in creatinine clearance below 15 ml/min the dose should be 50 mg every second day or 100 mg every fourth day.

MEDICINAL FORM AND PACKAGE:
Packages with 30 filmtablets of 50 and 100 mg.

STORAGE:
At a moderate temperature (15-30° C), in a place protected from humidity.

EXPIRY:
2 (two) years.